Sugi Predict

Sugi Predict / Compounds / SCHEMBL23439

SCHEMBL23439

SCHEMBL23439

COc1ccc(B(O)O)c(OC)c1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TUBB4A P04350 4/20 0.51
▸ TUBB P07437 4/20 0.51
▸ TUBA3C P0DPH7 4/20 0.51
▸ TUBA1B P68363 4/20 0.51
▸ TUBA4A P68366 4/20 0.51
▸ TUBB4B P68371 4/20 0.51
▸ TUBB3 Q13509 4/20 0.51
▸ TUBB2A Q13885 4/20 0.51
▸ TUBB8 Q3ZCM7 4/20 0.51
▸ TUBA3E Q6PEY2 4/20 0.51
▸ TUBA1A Q71U36 4/20 0.51
▸ TUBA1C Q9BQE3 4/20 0.51
▸ TUBB6 Q9BUF5 4/20 0.51
▸ TUBB2B Q9BVA1 4/20 0.51
▸ TUBB1 Q9H4B7 4/20 0.51
▸ ENPP2 Q13822 1/20 0.50
▸ ORAI1 Q96D31 1/20 0.43
▸ ORAI2 Q96SN7 1/20 0.43
▸ ORAI3 Q9BRQ5 1/20 0.43
▸ MAPT P10636 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29466487 1.00 TUBB4A (0.51) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL7715011 0.83 TUBB4A (0.43) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL6828096 0.83 TUBB4A (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3328067 0.83 TUBB4A (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3687594 0.83 TUBB4A (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1796152 0.83 TUBB4A (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL6828237 0.81 TUBB4A (0.47) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2592551 0.80 TUBB4A (0.41) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29401885 0.80 ENPP2 (0.65) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL263451 0.80 ENPP2 (0.65) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8361484-B2 Polymer systems for lung volume reduction therapy AERIS THERAPEUTICS, INC. (US) 2013-01-29 — — US claimed
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy CANADIAN IMPERIAL BANK OF COMMERCE (CA) 2010-02-18 — — US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 — — EP claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 — — WO claimed
CN-119528817-A TRPV6 small molecule inhibitor and preparation method and application thereof 湖南师范大学 2025-02-28 — — CN disclosed
US-20230192692-A1 MACROCYCLIC AND CAGE-LIKE MOLECULE BASED ON BIPHEN[n]ARENE AND DERIVATIVE, SYNTHESIS METHOD AND USE THEREOF TIANJIN NORMAL UNIVERSITY (CN) 2023-06-22 — — US disclosed
CN-116253687-A Diaryl pyrimidine compound and preparation method and application thereof 复旦大学 2023-06-13 — — CN disclosed
CN-109280032-B Pyridazinone mother nucleus structure histone deacetylase inhibitor and preparation method and application thereof 中国科学院上海药物研究所 2023-05-12 — — CN disclosed
EP-3118204-B1 O-PHENYL CHALCONE COMPOUND AND PREPARATION METHOD AND USE THEREOF NEOPANORA BIO TECH ZHUHAI LTD (CN) 2022-04-20 — — EP disclosed
US-20210317140-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2021-10-14 — — US disclosed
US-9988405-B2 O-phenyl chalcone compounds and uses thereof NEOPANORA BIO-TECHNOLOGY (ZHUHAI) LTD. (CN) 2018-06-05 — — US disclosed
US-9944597-B2 Polysubstituted pyrroles having microtubule-disrupting, cytotoxic and antitumor activities and methods of use thereof THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-04-17 — — US disclosed
US-20030009046-A1 Preparation of preparing substituted indanones EQUISTAR CHEMICALS, LP 2003-01-09 — — US disclosed
EP-0675118-B1 Biphenylderivatives, process for their preparation and their use as medicaments EISAI CO LTD (JP) 2002-10-09 — — EP disclosed
WO-2002070469-A2 SELECTIVE PDE3B INHIBITORS AND USE OF THE SAME IN THERAPY ICOS CORPORATION (US) 2002-09-12 — — WO disclosed
WO-2002070493-A1 BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY PHARMACOPEIA, INC. (US) 2002-09-12 — — WO disclosed
US-6281214-B1 USEFUL FOR TREATING AND AMELIORATING MENTAL DISORDERS EISAI CO., LTD (JP) 2001-08-28 — — US disclosed
CN-1290700-A Phenyl piperazine derivatives EISAI LTD (JP) 2001-04-11 — — CN disclosed
CN-1117966-A Biphenyl derivatives EISAI CO LTD (JP) 1996-03-06 — — CN disclosed
EP-0675118-A2 Biphenylderivatives, process for their preparation and their use as medicaments Eisai Co., Ltd. (JP) 1995-10-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192692-A1 MACROCYCLIC AND CAGE-LIKE MOLECULE BASED ON BIPHEN[n]ARENE AND DERIVATIVE, SYNTHESIS METHOD AND USE THEREOF TPMT, NUDT1, PNP TUBB4A 3407/4885TUBB 2925/4885TUBA3C 2782/4885
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy GFER, MUC1, CTH TUBB4A 1011/4885TUBB 612/4885TUBA3C 525/4885
US-20210317140-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB TUBB4A 2171/4885TUBB 1422/4885TUBA3C 2108/4885
US-20030009046-A1 Preparation of preparing substituted indanones CYP1A2, CYP1B1, CYP1A1 TUBB4A 2299/4885TUBB 2106/4885TUBA3C 1785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.